Pharma Groups Back Pfizer In 3rd Circ. Pay-For-Delay Case

Pharmaceutical groups on Monday asked the Third Circuit not to revive claims that Pfizer Inc. illegally paid Ranbaxy Laboratories Inc. to postpone its generic of cholesterol drug Lipitor, arguing that all...

Already a subscriber? Click here to view full article